Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-Transplant Renal Insufficiency Clear all
Completed Phase 2 Interventional Results available

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

NCT02544113
View directory record Official record
Conditions
Liver Failure
Interventions
Thymoglobulin, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Weston, Florida • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Jun 25, 2026, 10:10 PM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

NCT06741072
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions
Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21
Procedure · Drug · Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 25, 2026, 10:10 PM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jun 25, 2026, 10:10 PM EDT
Enrolling by invitation Early Phase 1 Interventional

RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

NCT05950724
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Etanercept Injection [Enbrel]
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 25, 2026, 10:10 PM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 10:10 PM EDT
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jun 25, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

NCT03810417
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Digoxin Antibodies Fab Fragments, Placebo, Baseline EO > 360 pM, EO < 360 pM
Drug · Other · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jun 25, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Jun 25, 2026, 10:10 PM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT00448708
View directory record Official record
Conditions
Kidney Diseases, ESRD
Interventions
Vascular Wrap Paclitaxel-Eluting Mesh, Lifespan® ePTFE Vascular Graft
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Jun 25, 2026, 10:10 PM EDT
Suspended No phase listed Observational

Role of Pancreatic Exocrine Secretion in Weight Gain After Pancreas Transplantation

NCT04690738
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Weight Gain
Interventions
Fecal Elastase Concentration
Diagnostic Test
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jun 25, 2026, 10:10 PM EDT
Not listed No phase listed Observational

Morbidity and Mortality Among Dialysis Patients After Treatment for Depression

NCT00442429
View directory record Official record
Conditions
Depression, ESRD
Interventions
Not listed
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Jun 25, 2026, 10:10 PM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 25, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

NCT00768729
View directory record Official record
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Sirolimus, MMF or Azathioprine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Madera, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jun 25, 2026, 10:10 PM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

NCT00311311
View directory record Official record
Conditions
Atherosclerosis, Kidney Failure
Interventions
tacrolimus, mycophenolate mofetil, prednisone, sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Jun 25, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Prevention and Early Detection and Intervention of Post-Coronary Artery Bypass Grafting Surgery (CABG) Acute Kidney Injury (AKI)

NCT02838667
View directory record Official record
Conditions
Acute Renal Injury, Preventive Measures
Interventions
Standard of Care plus Nephrology Care
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Jun 25, 2026, 10:10 PM EDT
Terminated Not applicable Interventional

Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT01033357
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Hyperplasia
Interventions
Graft, Vascular Wrap, Lifespan® ePTFE Vascular Graft Only
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Fresno, California • Inglewood, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jun 25, 2026, 10:10 PM EDT
Not listed Phase 1 Interventional

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

NCT03791476
View directory record Official record
Conditions
Kidney Failure
Interventions
rhC1INH, Saline Solution
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Jun 25, 2026, 10:10 PM EDT
Recruiting Phase 3 Interventional

Shingrix in Renal Transplant Recipients

NCT04128189
View directory record Official record
Conditions
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
Interventions
Shingrix
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 25, 2026, 10:10 PM EDT
Active, not recruiting Phase 3 Interventional

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT03386539
View directory record Official record
Conditions
Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions
Everolimus, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jun 25, 2026, 10:10 PM EDT
Terminated Phase 3 Interventional Results available

Everolimus Monotherapy as Immunosuppression After Liver Transplant

NCT04063865
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Jun 25, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease

NCT01001351
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Fresno, California • San Diego, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jun 25, 2026, 10:10 PM EDT